1
|
Rodeiro Guerra I, Herrea J, Cuétara E, Garrido G, Reyes E, Martínez I, Pérez CL, Fernández G, Hernández-Balmaseda I, Delgado R, Stingl JC, Berghe WV. Prevalence of ABCB1 3435C>T polymorphism in the Cuban population. Drug Metab Pers Ther 2021; 37:141-148. [PMID: 34860473 DOI: 10.1515/dmpt-2020-0156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 09/15/2021] [Indexed: 01/18/2023]
Abstract
OBJECTIVES ABCB1 gene polymorphisms can modify P-glycoprotein function with clinical consequences. METHODS The 3435C>T polymorphism prevalence was analyzed using oligonucleotide probes and next-generation sequencing in 421 unrelated healthy individuals living in Cuba. Data were stratified by gender, ethnic background and residence. The genotype and allelic frequencies were determined. RESULTS The genotype distribution met the Hardy-Weinberg equilibrium assumption. The allelic frequency was 63.5% for the 3435C variant. The genotype frequencies were 41.1% for CC, 44.9% for CT and 14.0% for TT. The allele and genotype distributions differed between individuals living in La Habana and Santiago de Cuba (p<0.05) when ethnic background was analyzed. The allelic distribution was similar among Admixed and Black subjects, and they differed from Caucasians. The CC genotype was equally distributed among Admixed and Black subjects, and they differed from Caucasians. The TT genotype frequency differed between Caucasians and Admixed. The CT genotype was distributed differently among the three groups. Similar distribution was obtained in Brazilians, whereas some similarities were observed in African, Spanish and Chinese populations, consistent with the mixed Cuban ethnic origin. CONCLUSIONS This is the first report on allele and genotype frequencies of the 3435C>T polymorphism in Cuba, which may support personalized medicine programs.
Collapse
Affiliation(s)
- Idania Rodeiro Guerra
- Departamento de Farmacología, Instituto de Ciencias del Mar (ICIMAR), La Habana, Cuba
| | - Jose Herrea
- Instituto de Ciencia y Tecnología de Materiales, IMRE, Universidad de La Habana, La Habana, Cuba
| | - Elizabeth Cuétara
- Departamento de Farmacología, Instituto Nacional de Oncología y Radiobiología (INOR), La Habana, Cuba
| | - Gabino Garrido
- Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad de Católica del Norte, Antofagasta, Chile
| | - Elizabeth Reyes
- Departamento de Farmacología, Instituto Nacional de Oncología y Radiobiología (INOR), La Habana, Cuba
| | - Ioanna Martínez
- Instituto de Ciencias Básicas y Preclínicas Victoria de Girón (ICBP), Universidad de Ciencias Médicas de La Habana (UCMH), La Habana, Cuba
| | - Carlos L Pérez
- Instituto de Ciencias Básicas y Preclínicas Victoria de Girón (ICBP), Universidad de Ciencias Médicas de La Habana (UCMH), La Habana, Cuba
| | - Gisselle Fernández
- Instituto de Ciencias Básicas y Preclínicas Victoria de Girón (ICBP), Universidad de Ciencias Médicas de La Habana (UCMH), La Habana, Cuba
| | | | - René Delgado
- Instituto de Farmacia y Alimentos (IFAL), Universidad de La Habana, La Habana, Cuba.,Facultad de Ciencias Naturales y Agropecuarias, Universidad de Santander (UDES), Bucaramanga, Colombia
| | - Julia C Stingl
- Institute of Clinical Pharmacology, University Hospital of RWTH Aachen, Aachen, Germany
| | - Wim Vanden Berghe
- Laboratory of Protein Science, Proteomics and Epigenetic Signaling (PPES), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium
| |
Collapse
|
2
|
Human variability in influx and efflux transporters in relation to uncertainty factors for chemical risk assessment. Food Chem Toxicol 2020; 140:111305. [DOI: 10.1016/j.fct.2020.111305] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Revised: 03/20/2020] [Accepted: 03/23/2020] [Indexed: 12/11/2022]
|
3
|
Céspedes-Garro C, Naranjo MEG, Rodrigues-Soares F, LLerena A, Duconge J, Montané-Jaime LK, Roblejo H, Fariñas H, Campos MDLA, Ramírez R, Serrano V, Villagrán CI, Peñas-LLedó EM. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics 2016; 17:1707-1724. [PMID: 27633613 DOI: 10.2217/pgs-2016-0053] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
AIM The present review was aimed at analyzing the pharmacogenetic scientific activity in Central America and the Caribbean. MATERIALS & METHODS A literature search for pharmacogenetic studies in each country of the region was conducted on three databases using a list of the most relevant pharmacogenetic biomarkers including 'phenotyping probe drugs' for major drug metabolizing enzymes. The review included 132 papers involving 47 biomarkers and 35,079 subjects (11,129 healthy volunteers and 23,950 patients). RESULTS The country with the most intensive pharmacogenetic research was Costa Rica. The most studied medical therapeutic area was oncology, and the most investigated biomarkers were CYP2D6 and HLA-A/B. Conclusion: Research activity on pharmacogenetics in Central American and the Caribbean populations is limited or absent. Therefore, strategies to promote effective collaborations, and foster interregional initiatives and research efforts among countries from the region could help for the rational clinical implementation of pharmacogenetics and personalized medicine.
Collapse
Affiliation(s)
- Carolina Céspedes-Garro
- CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain.,RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics.,Teaching & Research Department, Genetics Section, School of Biology, University of Costa Rica, San José, Costa Rica
| | - María-Eugenia G Naranjo
- CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain.,RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics
| | - Fernanda Rodrigues-Soares
- RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics.,Departamento de Biologia Geral, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Adrián LLerena
- CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain.,RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics
| | - Jorge Duconge
- RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics.,Pharmaceutical Sciences Department, School of Pharmacy, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico
| | - Lazara K Montané-Jaime
- Pharmacology Unit Department of Paraclinical Sciences, Faculty of Medical Sciences, The University of West Indies, St Augustine, Trinidad & Tobago
| | - Hilda Roblejo
- RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics.,Teaching & Research Department, National Center of Medical Genetics, Havana, Cuba
| | - Humberto Fariñas
- CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain
| | - María de Los A Campos
- Secretaría Ejecutiva del Consejo de Ministros de Salud de Centroamérica y República Dominicana, Ciudad Merliot, El Salvador
| | - Ronald Ramírez
- RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics.,Facultad de Medicina, UNAN Universidad Autónoma Nacional de Nicaragua, León, Nicaragua
| | - Víctor Serrano
- RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics.,CIIMET Centro de Investigación e Información de Medicamentos y Tóxicos, Facultad de Medicina, Universidad de Panamá, Panamá, Panamá
| | - Carmen I Villagrán
- RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics.,Facultad de Ciencias Médicas, Dirección de Investigación, Universidad de San Carlos de Guatemala, Guatemala
| | - Eva M Peñas-LLedó
- CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain.,RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics
| |
Collapse
|
4
|
Kassogue Y, Dehbi H, Nassereddine S, Quachouh M, Nadifi S. Genotype variability and haplotype frequency of MDR1 (ABCB1) gene polymorphism in Morocco. DNA Cell Biol 2013; 32:582-8. [PMID: 23930592 DOI: 10.1089/dna.2013.2108] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
The multidrug resistance gene (MDR1) plays an important role in the transport of a wide range of drugs and elimination of xenobiotics from the body. Identification of polymorphisms and haplotypes in the MDR1 gene might not only help understand pharmacokinetics and pharmacodynamics of drugs, but also can help in the prediction of drug responses, toxicity, and side effects, especially, in the era of personalized medicine. We have analyzed the genotypic and haplotypic frequencies of the three most common single-nucleotide polymorphisms in the MDR1 gene in a sample of 100 unrelated healthy Moroccan subjects by polymerase chain reaction-restrictive fragment length polymorphism. The observed genotype frequencies were 43% for 1236CC, 49% for 1236CT, and 8% for 1236TT in exon 12; 49% for 2677GG, 47% for 2677GT, and 4% for 2677TT in exon 21; 39% for 3435CC, 51% 3435CT for 3435TT, and 10% for 3435TT in exon 26, respectively. We found that all polymorphisms were in Hardy-Weinberg equilibrium. Moderate linkage disequilibrium (LD) was observed between the three polymorphisms, the strongest LD in our study has been observed between C1236T and G2677T (D'=0.76; r(2)=0.45). We identified eight haplotypes, the most frequent were 1236C-2677G-3435C (53%), 1236T-2677T-3435T (21%), and 1236C-2677G-3435T (10%), respectively. Our findings might facilitate future studies on pharmacokinetics of P-glycoprotein substrate drugs and interindividual variability to drugs in Moroccan patients.
Collapse
Affiliation(s)
- Yaya Kassogue
- 1 Genetics and Molecular Pathology Laboratory, Medical School of Casablanca, University Hassan II , Casablanca, Morocco
| | | | | | | | | |
Collapse
|
5
|
Umamaheswaran G, Krishna Kumar D, Kayathiri D, Rajan S, Shewade DG, Dkhar SA, Manjunath S, Ushakiran P, Reneega G, Ritushree K, Adithan C. Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population. Mol Biol Rep 2012; 39:6343-51. [PMID: 22318545 DOI: 10.1007/s11033-012-1456-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Accepted: 01/23/2012] [Indexed: 01/18/2023]
Abstract
Molecular variants of polymorphic drug metabolizing enzymes and drug transporters are attributed to differences in individual's therapeutic response and drug toxicity in different populations. We sought to determine the genotype and allele frequencies of polymorphisms for major phase II drug-metabolizing enzymes (TPMT, UGT1A1) and drug transporter (MDR1) in South Indians. Allelic variants of TPMT (*2,*3A,*3B,*3C & *8), UGT1A1 (TA)6>7 and MDR1 (2677G>T/A & 3435C>T) were evaluated in 450-608 healthy South Indian subjects. Genomic DNA was extracted by phenol-chloroform method and genotype was determined by PCR-RFLP, qRT-PCR, allele specific PCR, direct sequencing and SNaPshot techniques. The frequency distributions of TPMT, UGT1A1 and MDR1 gene polymorphisms were compared between the individual 4 South Indian populations viz., Tamilian, Kannadiga, Andhrite and Keralite. The combined frequency distribution of the South Indian populations together, was also compared with that of other major populations. The allele frequencies of TPMT*3C, UGT1A1 (TA)7, MDR1 2677T, 2677A and 3435T were 1.2, 39.8, 60.3, 3.7, and 61.6% respectively. The other variant alleles such as TPMT*2, *3A, *3B and *8 were not identified in the South Indian population. Sub-population analysis showed that the distribution of UGT1A1 (TA)6>7 and MDR1 allelic variants differed between the four ethnic groups. However, the frequencies of TPMT*3C allele were similar in the four South Indian populations. The distribution of TPMT, UGT1A1 and MDR1 gene polymorphisms of the South Indian population was significantly different from other populations.
Collapse
Affiliation(s)
- Gurusamy Umamaheswaran
- ICMR Centre for Advance Research in Pharmacogenomics, Department of Pharmacology, JIPMER, Pondicherry, India.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep 2011; 63:808-14. [DOI: 10.1016/s1734-1140(11)70593-x] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2010] [Revised: 12/28/2010] [Indexed: 01/11/2023]
|
7
|
Sipeky C, Csongei V, Jaromi L, Safrany E, Maasz A, Takacs I, Beres J, Fodor L, Szabo M, Melegh B. Genetic Variability and Haplotype Profile of MDR1 (ABCB1) in Roma and Hungarian Population Samples with a Review of the Literature. Drug Metab Pharmacokinet 2011; 26:206-15. [DOI: 10.2133/dmpk.dmpk-10-sc-068] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Janneh O, Bray PG, Jones E, Wyen C, Chiba P, Back DJ, Khoo SH. Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2010; 65:906-16. [PMID: 20237075 DOI: 10.1093/jac/dkq082] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND The intracellular and plasma concentrations of HIV protease inhibitors (HPIs) vary widely in vivo. It is unclear whether there is a concentration-dependent effect of HPIs such that at increasing concentration they may either block their own efflux (leading to 'autoboosting') or influx (leading to saturability/decreased intracellular accumulation). METHOD The effects of various concentrations (0-30 microM) of lopinavir, saquinavir, ritonavir and atazanavir on the accumulation of [(14)C]lopinavir, [(3)H]saquinavir, [(3)H]ritonavir and [(3)H]atazanavir, respectively, were investigated in CEM(parental), CEM(VBL) [P-glycoprotein (ABCB1) overexpressing], CEM(E1000) (MRP1 overexpressing) and in peripheral blood mononuclear cells (PBMCs). We also investigated the effects of inhibitors of ABCB1/ABCG2 (tariquidar), ABCC (MK571) and ABCC1/2 (frusemide), singly and in combination with HPIs, on cellular accumulation. RESULTS In all the cell lines, with increasing concentration of lopinavir, saquinavir and ritonavir, there was a significant increase in the cellular accumulation of [(14)C]lopinavir, [(3)H]saquinavir and [(3)H]ritonavir. Tariquidar, MK571 and frusemide (alone and in combination with lopinavir, saquinavir and ritonavir) significantly increased the accumulation of [(14)C]lopinavir, [(3)H]saquinavir and [(3)H]ritonavir. Ritonavir (alone or in combination with tariquidar) decreased the intracellular accumulation of [(3)H]ritonavir in PBMCs. Atazanavir decreased the accumulation of [(3)H]atazanavir in a concentration-dependent manner in all of the cells tested. CONCLUSIONS There are complex and variable drug-specific rather than class-specific effects of the HPIs on their own accumulation.
Collapse
Affiliation(s)
- Omar Janneh
- Department of Biomolecular and Sport Sciences, James Starley Building, Priory Street, Coventry University, Coventry CV1 5FB, UK
| | | | | | | | | | | | | |
Collapse
|